PARP Inhibition in the Treatment of Pancreatic Cancer: Current and Future Perspectives on Personalized Therapy

Download All
Learn how experts around the world use PARP inhibitors to optimally manage patients with pancreatic cancer and BRCA1/2 or other alterations causing homologous repair deficiency with focused commentaries, a podcast series, an expert video roundtable, and downloadable slideset.
Elena Gabriela Chiorean, MD
Eileen M. O'Reilly, MD
Philip Agop Philip, MD, PhD, FRCP
person default
Naureen Starling, BSc(Hons), MBBS, MD(Res), FRCP

Audio Podcast Series with Podcast Pearls Transcript

Listen to Philip Agop Philip, MD, PhD, FRCP, and Elena Gabriela Chiorean, MD, discuss the role of testing for biomarkers and the current paradigm of PARP inhibitor therapy in the treatment of pancreatic cancer.

Elena Gabriela Chiorean, MD Philip Agop Philip, MD, PhD, FRCP Released: October 26, 2021

In this downloadable PDF summary from a CCO podcast, Philip Philip, MD, PhD and Elena Chiorean, MD discuss the role of biomarker testing and PARP inhibitors in the treatment of pancreatic cancer.

Elena Gabriela Chiorean, MD Philip Agop Philip, MD, PhD, FRCP Released: November 3, 2021

Listen to Eileen M. O’Reilly, MD, and Naureen Starling, MD, FRCP, discuss emerging therapeutic strategies involving PARP inhibitors that are being investigated for the treatment of pancreatic cancer.

Eileen M. O'Reilly, MD person default Naureen Starling, BSc(Hons), MBBS, MD(Res), FRCP Released: February 21, 2022

In this downloadable PDF summary from a CCO podcast, Eileen M. O’Reilly, MD, and Naureen Starling, MD, FRCP, compare the role and use of PARP inhibitors in the treatment of pancreatic cancer between the United States and Europe.

Eileen M. O'Reilly, MD person default Naureen Starling, BSc(Hons), MBBS, MD(Res), FRCP Released: May 3, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings